

## Listing and evaluation of the results

51396: Dr. Endre Mikus  
LabMagister Training and Science Ltd.

Survey of 16 September 2022

Adviser:

Prof. Dr. med. Kai Gutensohn  
INSTAND e.V.  
Ubierstraße 20  
40223 Düsseldorf

Tel.: +49 160 1549548  
Mail: k.gutensohn@instand-ev.de

217

### Haematology 11 - Stem/Progenitor Cells (CD 34)

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
CD34+ Events	51	/µl	34.0	38.4	SV	30.7	46.1	-11.5%	-1,12	+	
	52		49.0	69.1	SV	55.3	82.9	-29.1%	-2,86	-	
Leucocytes	(1) 51	/µl	10490								
	(1) 52		13742								
CD45+ events (single platform)	(1) 51	/µl	10103								
	(1) 52		12736								
Viable CD45+ Events	(1) 51	/µl	9945								
	(1) 52		12611								
Viable CD34+ Events	51	/µl	33.0	37.6	SV	30.1	45.1	-12.2%	-1,13	+	
	52		48.0	65.8	SV	52.6	79.0	-27.1%	-2,89	-	
Viable CD34+ Events per viable CD45+ Events	(1) 51	%	0.340								
	(1) 52		0.380								

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Sample reception date	Sample processing date
CD34+ Events	51		34.0	1.00	222	BN	BN04	09/07/22	09/07/22
	52		49.0	1.00					
Leucocytes	51		10490	1.00	222	BN	BN04	09/07/22	09/07/22
	52		13742	1.00					
CD45+ events (single platform)	51		10103	1.00	222	BN	BN04	09/07/22	09/07/22
	52		12736	1.00					
Viable CD45+ Events	51		9945	1.00	222	BN	BN04	09/07/22	09/07/22
	52		12611	1.00					
Viable CD34+ Events	51		33.0	1.00	222	BN	BN04	09/07/22	09/07/22
	52		48.0	1.00					
Viable CD34+ Events per viable CD45+ Events	51		0.340	1.00	222	BN	BN04	09/07/22	09/07/22
	52		0.380	1.00					

(1) In general, no certificate is issued for this parameter in this EQA scheme.

## Individual summary of results

51396: Dr. Endre Mikus  
LabMagister Training and Science Ltd.

Survey of 16 September 2022



217

### Haematology 11 - Stem/Progenitor Cells (CD 34)

#### CD34+ Events (/μl, N = 102)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	38.4	30.7 - 46.1	38.4	10.2	102	89.2	81.4
	52	69.1	55.3 - 82.9	69.1	10.2	102	86.3	


Rate of success: 81,4%



#### Leucocytes (/μl, N = 34)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51			10900		34		
	52			13959		34		


Rate of success: 94,1%



#### CD45+ events (single platform) (/μl, N = 99)


Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51			10852		99		
	52			13792		99		

Rate of success: 90,9%





Viable CD45+ Events (/μl, N = 104)									
Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	51			9300		104			
	52			11128		104			

Rate of success: 85,6%



Viable CD34+ Events (/μl, N = 106)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
all methods	51	37.6	30.1 - 45.1	37.6	10.8	106	88.7	83.0		
	52	65.8	52.6 - 79.0	65.8	9.36	106	92.5			

Rate of success: 83%



Viable CD34+ Events per viable CD45+ Events (% , N = 108)									
Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	51			0.406		108			
	52			0.594		108			

Rate of success: 85,2%

